Literature DB >> 35831509

Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.

Jason J Kwon1,2,3, Behnoush Hajian4, Yuemin Bian4, Lucy C Young5, Alvaro J Amor4, James R Fuller6, Cara V Fraley4, Abbey M Sykes3,4, Jonathan So1,2,3, Joshua Pan1,2,3, Laura Baker4, Sun Joo Lee1,2,3, Douglas B Wheeler1,2, David L Mayhew1,2,3, Nicole S Persky7, Xiaoping Yang7, David E Root7, Anthony M Barsotti8, Andrew W Stamford8, Charles K Perry4, Alex Burgin4, Frank McCormick5,9, Christopher T Lemke10, William C Hahn11,12,13,14, Andrew J Aguirre15,16,17,18.   

Abstract

Receptor tyrosine kinase (RTK)-RAS signalling through the downstream mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and survival. The SHOC2-MRAS-PP1C holophosphatase complex functions as a key regulator of RTK-RAS signalling by removing an inhibitory phosphorylation event on the RAF family of proteins to potentiate MAPK signalling1. SHOC2 forms a ternary complex with MRAS and PP1C, and human germline gain-of-function mutations in this complex result in congenital RASopathy syndromes2-5. However, the structure and assembly of this complex are poorly understood. Here we use cryo-electron microscopy to resolve the structure of the SHOC2-MRAS-PP1C complex. We define the biophysical principles of holoenzyme interactions, elucidate the assembly order of the complex, and systematically interrogate the functional consequence of nearly all of the possible missense variants of SHOC2 through deep mutational scanning. We show that SHOC2 binds PP1C and MRAS through the concave surface of the leucine-rich repeat region and further engages PP1C through the N-terminal disordered region that contains a cryptic RVXF motif. Complex formation is initially mediated by interactions between SHOC2 and PP1C and is stabilized by the binding of GTP-loaded MRAS. These observations explain how mutant versions of SHOC2 in RASopathies and cancer stabilize the interactions of complex members to enhance holophosphatase activity. Together, this integrative structure-function model comprehensively defines key binding interactions within the SHOC2-MRAS-PP1C holophosphatase complex and will inform therapeutic development .
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35831509     DOI: 10.1038/s41586-022-04928-2

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  44 in total

1.  A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.

Authors:  Pablo Rodriguez-Viciana; Juan Oses-Prieto; Alma Burlingame; Mike Fried; Frank McCormick
Journal:  Mol Cell       Date:  2006-04-21       Impact factor: 17.970

Review 2.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

3.  Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy.

Authors:  Erin M Higgins; J Martijn Bos; Heather Mason-Suares; David J Tester; Jaeger P Ackerman; Calum A MacRae; Katia Sol-Church; Karen W Gripp; Raul Urrutia; Michael J Ackerman
Journal:  JCI Insight       Date:  2017-03-09

4.  Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.

Authors:  Tim Wang; Haiyan Yu; Nicholas W Hughes; Bingxu Liu; Arek Kendirli; Klara Klein; Walter W Chen; Eric S Lander; David M Sabatini
Journal:  Cell       Date:  2017-02-02       Impact factor: 41.582

5.  De novo missense variants in PPP1CB are associated with intellectual disability and congenital heart disease.

Authors:  Lijiang Ma; Yavuz Bayram; Heather M McLaughlin; Megan T Cho; Alyson Krokosky; Clesson E Turner; Kristin Lindstrom; Caleb P Bupp; Katey Mayberry; Weiyi Mu; Joann Bodurtha; Veronique Weinstein; Neda Zadeh; Wendy Alcaraz; Zöe Powis; Yunru Shao; Daryl A Scott; Andrea M Lewis; Janson J White; Shalani N Jhangiani; Elif Yilmaz Gulec; Seema R Lalani; James R Lupski; Kyle Retterer; Rhonda E Schnur; Ingrid M Wentzensen; Sherri Bale; Wendy K Chung
Journal:  Hum Genet       Date:  2016-09-28       Impact factor: 4.132

6.  A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.

Authors:  Karen W Gripp; Kimberly A Aldinger; James T Bennett; Laura Baker; Jessica Tusi; Nina Powell-Hamilton; Deborah Stabley; Katia Sol-Church; Andrew E Timms; William B Dobyns
Journal:  Am J Med Genet A       Date:  2016-06-05       Impact factor: 2.802

7.  SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.

Authors:  Lucy C Young; Nicole Hartig; Isabel Boned Del Río; Sibel Sari; Benjamin Ringham-Terry; Joshua R Wainwright; Greg G Jones; Frank McCormick; Pablo Rodriguez-Viciana
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

8.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Authors:  Fiona M Behan; Francesco Iorio; Gabriele Picco; Kosuke Yusa; Mathew J Garnett; Emanuel Gonçalves; Charlotte M Beaver; Giorgia Migliardi; Rita Santos; Yanhua Rao; Francesco Sassi; Marika Pinnelli; Rizwan Ansari; Sarah Harper; David Adam Jackson; Rebecca McRae; Rachel Pooley; Piers Wilkinson; Dieudonne van der Meer; David Dow; Carolyn Buser-Doepner; Andrea Bertotti; Livio Trusolino; Euan A Stronach; Julio Saez-Rodriguez
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

Review 9.  Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.

Authors:  Karen W Gripp; Angela E Lin
Journal:  Genet Med       Date:  2012-03       Impact factor: 8.822

10.  Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair.

Authors:  Viviana Cordeddu; Elia Di Schiavi; Len A Pennacchio; Avi Ma'ayan; Anna Sarkozy; Valentina Fodale; Serena Cecchetti; Alessio Cardinale; Joel Martin; Wendy Schackwitz; Anna Lipzen; Giuseppe Zampino; Laura Mazzanti; Maria C Digilio; Simone Martinelli; Elisabetta Flex; Francesca Lepri; Deborah Bartholdi; Kerstin Kutsche; Giovanni B Ferrero; Cecilia Anichini; Angelo Selicorni; Cesare Rossi; Romano Tenconi; Martin Zenker; Daniela Merlo; Bruno Dallapiccola; Ravi Iyengar; Paolo Bazzicalupo; Bruce D Gelb; Marco Tartaglia
Journal:  Nat Genet       Date:  2009-08-16       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.